NORTH CHICAGO, Ill., Aug. 16, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved ...

NORTH CHICAGO, Ill., June 4, 2020 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced new long-term results showing that once daily upadacitinib ...

NORTH CHICAGO, Ill., Nov. 9, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new results from a post-hoc analysis of the Phase 3 SELECT-BEYOND clinical trial evaluating RINVOQ ® (upadacitinib ...

The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...

The Food and Drug Administration (FDA) has approved Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis (RA) who ...

The FDA just gave a thumbs-up to rheumatoid arthritis drug Rinvoq. It could become AbbVie's biggest immunology blockbuster after Humira. On Friday, AbbVie added another key FDA approval with a ...

NORTH CHICAGO, Ill., Jan. 25, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV), today announced that the European Commission (EC) has approved RINVOQTM (upadacitinib, 15 mg), an oral, once daily selective and ...

With its Allergan merger likely in the final stages, AbbVie is placing its hopes in a pair of home-grown drugs to help weather biosimilar attacks against Humira. One of those, JAK inhibitor Rinvoq, ...

When the FDA dropped the bombshell that it would add more safety warnings and restrict the use of JAK inhibitors, industry watchers began weighing the impact on a key player: AbbVie’s Rinvoq. But ...

Rinvoq (upadacitinib) is a brand-name tablet that’s prescribed for rheumatoid arthritis and certain other conditions. The cost of the drug with and without insurance can depend on several factors, ...